脊柱关节炎外周关节炎活动度测量工具的比较分析:13项随机对照试验的测量性能研究
本研究利用13项随机对照试验(RCT)的个体患者数据,评估用于评估中轴型和外周型脊柱关节炎(axSpA/pSpA)外周关节炎的多种测量工具的测量性能。结果显示复合评分(如BASDAI、ASDAS、DAPSA44)总体上比单项目工具表现更稳健,单项目工具在临床试验区分度上被评为RED。
要点
- 复合评分(BASDAI、ASDAS、DAPSA44)在axSpA和pSpA中总体表现优于单项目工具。
- 单项目工具在axSpA临床试验区分度上均为RED,PGA的重测信度也为RED。
- axSpA中所有工具的结构效度和意义阈值均为AMBER/GREEN,反应性一致为GREEN。
核心结论
- 复合评分如BASDAI、ASDAS和DAPSA44在评估axSpA和pSpA外周关节炎活动度时总体表现比单项目工具更稳健。
- 该研究为axSpA和pSpA外周关节炎活动度测量工具提供了首个基于RCT的综合测量性能评估。
研究设计与样本
- 研究纳入13项RCT(10项axSpA和3项pSpA),使用个体患者数据评估测量性能。
- 评估工具包括PGA、44或66/68关节肿胀/压痛关节计数、CRP、BASDAI、ASDAS、DAPSA44和44关节DAS。
- axSpA分析仅限于基线时存在外周关节炎的患者。
- 采用基于OMERACT的GREEN/AMBER/RED评级综合证据,并评估偏倚风险。
主要发现
- axSpA试验中基线外周关节炎患者比例为25-51%,各研究SJC44中位数为2-3。
- pSpA试验中SJC44中位数为2-5。
- axSpA中所有工具的结构效度和意义阈值为AMBER/GREEN,仅PGA的重测信度为RED。
- axSpA中反应性一致为GREEN,单项目工具的临床试验区分度为RED,复合评分一致为GREEN。
- pSpA中多数工具表现为AMBER/GREEN,但SJC44的区分度为RED。
关键数值与推荐
- axSpA试验基线外周关节炎比例为25-51%,SJC44中位数2-3。
- pSpA试验SJC44中位数2-5。
- 测量性能评级采用GREEN/AMBER/RED分别对应低/不确定/高偏倚风险和良好/足够/差的表现。
临床怎么用
- 在axSpA和pSpA外周关节炎活动度评估中,优先选用BASDAI、ASDAS、DAPSA44等复合评分而非单项目工具。
- 单项目工具(如PGA)在临床试验区分度和重测信度方面表现不足,不宜单独用于疗效区分。
局限性
- 分析仅基于13项RCT的个体患者数据,axSpA分析限于基线有外周关节炎的患者。
- 研究未报告各工具在临床实践场景中的外部验证结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Using randomised controlled trial (RCT) data, this study evaluated the measurement properties of selected instruments to assess peripheral arthritis in axial and peripheral spondyloarthritis (axSpA/pSpA) and to inform selection of the best-performing instrument. METHODS: Eligible studies were RCTs in axSpA or pSpA with individual patient data available to calculate Patient Global Assessment (PGA), swollen/tender joint counts (44 or 66/68 joints), C reactive protein, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Axial Spondyloarthritis Disease Activity Score, Disease Activity Index for Psoriatic Arthritis/Disease Activity in Psoriatic Arthritis with 44 joint count (DAPSA44) and 44-joint Disease Activity Score at baseline and timing of primary endpoint. In axSpA, analyses were restricted to patients with peripheral arthritis at baseline. Measurement properties assessed included construct validity, test-retest reliability, longitudinal construct validity, trial discrimination and thresholds of meaning. Risk of bias (RoB) was evaluated and evidence was synthesised using Outcome Measures in Rheumatology-based GREEN/AMBER/RED ratings (low/uncertain/high RoB and good/adequate/poor performance, respectively). RESULTS: 13 RCTs were included (10 axSpA and 3 pSpA). In axSpA trials, 25-51% of patients had peripheral arthritis at baseline (median swollen joint count of 44 joints (SJC44) across studies: 2-3); in pSpA trials, median SJC44 ranged 2-5. In axSpA, construct validity and thresholds of meaning were rated AMBER/GREEN for all instruments, while test-retest reliability was RED only for PGA. Responsiveness was consistently GREEN. Clinical trial discrimination was RED for single-item instruments but consistently GREEN for composite scores. In pSpA, most instruments showed AMBER/GREEN performance, although SJC44 demonstrated RED discrimination. CONCLUSIONS: This study provides the first comprehensive, trial-based evaluation of measurement properties for instruments assessing peripheral arthritis activity in axSpA and pSpA. Composite scores, such as BASDAI, ASDAS and DAPSA44, generally demonstrated more robust performance than single-item instruments, expanding the evidence base for the final instrument-selection phase.
引用
- Capelusnik D, López-Medina C, Webers C, et al. Comparative analysis of instruments measuring peripheral arthritis activity in Spondyloarthritis: a measurement properties study in 13 RCTs. RMD Open. 2026. PMID: 42791027. doi:10.1136/rmdopen-2026-007207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。